Loading
Enzalutamide gave clinical benefit at 16 weeks to a quarter of women with androgen receptor-expressing triple-negative breast cancer, a third among those with 10% or more staining, with fatigue the only common severe side effect.
Phase 2 study of enzalutamide 160 mg daily in locally advanced or metastatic AR-positive TNBC (nuclear AR staining above 0% by a breast-optimised assay). Of 118 enrolled, 78 were evaluable (10% or more nuclear AR with a post-baseline assessment). Clinical benefit at 16 weeks was 25% (intention-to-treat) and 33% (evaluable); median progression-free survival 2.9 and 3.3 months; median overall survival 12.7 and 17.6 months. Fatigue was the only grade 3 or higher related event above 2%.
Enzalutamide works modestly in AR-positive TNBC and is the reference for the LAR subtype's therapy implication; the AR threshold used for eligibility changes who counts as positive.
Shares Androgen receptor signalling, Androgen receptor, Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Peter Schmid, Metastatic triple-negative breast cancer, Journal of Clinical Oncology, Triple-negative breast cancer (TNBC).
Shares Enzalutamide, Androgen receptor, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Enzalutamide, Androgen receptor, Triple-negative breast cancer (TNBC).
Shares Enzalutamide, Androgen receptor.
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).
Shares Metastatic triple-negative breast cancer, Triple-negative breast cancer (TNBC).